Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has announced a significant advancement in its CDX bi-specific antibody development for treating relapsed/refractory acute myeloid leukaemia (AML), a subset of acute lymphoblastic leukaemia (ALL), and potentially for conditioning in bone marrow transplantations. The company's scientists have created an improved version of CDX using Lonza's bYlok bispecific pairing technology, which has shown enhanced efficacy in in vitro testing. Additional in vivo studies are currently underway.
CEO Dr. Vladislav Sandler highlighted the potential of this development to improve treatment outcomes for patients with often incurable blood cancers. The advancement could accelerate the product candidate's progress towards clinical trials and potentially attract new industry partners interested in co-developing CDX.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) ha annunciato un'importante avanzamento nello sviluppo del suo anticorpo bispecifico CDX per il trattamento della leucemia mieloide acuta (AML) recidivante/resistente, una sottocategoria della leucemia linfoblastica acuta (ALL), e potenzialmente per la preparazione nei trapianti di midollo osseo. I scienziati dell'azienda hanno creato una versione migliorata di CDX utilizzando la tecnologia di abbinamento bispecifico bYlok di Lonza, che ha dimostrato un'efficacia migliorata nei test in vitro. Ulteriori studi in vivo sono attualmente in corso.
Il CEO Dr. Vladislav Sandler ha sottolineato il potenziale di questo sviluppo per migliorare i risultati terapeutici per i pazienti con malattie ematiche spesso incurabili. Questo progresso potrebbe accelerare il percorso del candidato prodotto verso le sperimentazioni cliniche e potenzialmente attrarre nuovi partner del settore interessati a co-sviluppare CDX.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) ha anunciado un avance significativo en el desarrollo de su anticuerpo biespecífico CDX para tratar la leucemia mieloide aguda (AML) en recaída/resistencia, un subconjunto de la leucemia linfoblástica aguda (ALL), y potencialmente para la preparación en trasplantes de médula ósea. Los científicos de la empresa han creado una versión mejorada de CDX utilizando la tecnología de emparejamiento biespecífico bYlok de Lonza, que ha demostrado una eficacia mejorada en pruebas in vitro. Estudios adicionales en vivo están actualmente en marcha.
El CEO Dr. Vladislav Sandler destacó el potencial de este desarrollo para mejorar los resultados del tratamiento para pacientes con cánceres sanguíneos a menudo incurables. Este avance podría acelerar el progreso del candidato del producto hacia ensayos clínicos y atraer potencialmente nuevos socios de la industria interesados en co-desarrollar CDX.
Hemogenyx Pharmaceuticals plc (LSE:HEMO)는 재발/불응성 급성 골수 백혈병(AML), 급성 림프구 백혈병(ALL)의 하위 집합, 그리고 잠재적으로 골수 이식에 대한 조건으로 치료하기 위한 CDX 이중 특이성 항체 개발의 중요한 진전을 발표했습니다. 회사 과학자들은 Lonza의 bYlok 이중 특이성 페어링 기술을 사용하여 CDX의 개선된 버전을 만들었으며, 이는 시험관 내 테스트에서 향상된 효능을 보여주었습니다. 추가 생체 내 연구가 현재 진행 중입니다.
CEO 드. 블라디슬라프 샌들러는 이 개발이 종종 치료가 불가능한 혈액암 환자들의 치료 결과를 개선할 가능성을 강조했습니다. 이 발전은 임상 시험을 위한 제품 후보의 진행을 가속화하고 CDX의 공동 개발에 관심이 있는 새로운 산업 파트너를 유치할 수 있습니다.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) a annoncé un avancement significatif dans le développement de son anticorps bispécifique CDX pour traiter la leucémie myéloïde aiguë (AML) récidivante/résistante, un sous-ensemble de la leucémie lymphoblastique aiguë (ALL), et potentiellement pour la préparation lors des transplantations de moelle osseuse. Les scientifiques de l'entreprise ont créé une version améliorée de CDX utilisant la technologie d'appariement bispécifique bYlok de Lonza, qui a montré une efficacité accrue lors des tests in vitro. Des études in vivo sont actuellement en cours.
Le PDG Dr. Vladislav Sandler a souligné le potentiel de ce développement pour améliorer les résultats des traitements pour les patients atteints de cancers du sang souvent incurables. Cette avancée pourrait accélérer la progression du candidat médicament vers les essais cliniques et potentiellement attirer de nouveaux partenaires industriels intéressés par le co-développement de CDX.
Die Hemogenyx Pharmaceuticals plc (LSE:HEMO) hat einen bedeutenden Fortschritt in der Entwicklung ihres CDX-bispezifischen Antikörpers zur Behandlung von wiederkehrender/refraktärer akuter myeloischer Leukämie (AML), einer Untergruppe der akuten lymphoblastischen Leukämie (ALL), und potenziell zur Vorbereitung von Knochenmarktransplantationen, angekündigt. Die Wissenschaftler des Unternehmens haben eine verbesserte Version von CDX unter Verwendung der bYlok-bispezifischen Paarungstechnologie von Lonza geschaffen, die eine verbesserte Wirksamkeit in In-vitro-Tests gezeigt hat. Zusätzliche in-vivo-Studien sind derzeit im Gange.
CEO Dr. Vladislav Sandler hob das Potenzial dieser Entwicklung hervor, um die Behandlungsergebnisse für Patienten mit oft unheilbaren Blutkrebserkrankungen zu verbessern. Der Fortschritt könnte den Verlauf des Produktkandidaten in Richtung klinischer Studien beschleunigen und potenziell neue Industriepartner anziehen, die an der gemeinsamen Entwicklung von CDX interessiert sind.
- Development of an improved version of CDX bi-specific antibody
- Enhanced efficacy demonstrated in in vitro testing
- Potential for accelerated development towards clinical trials
- Possibility of attracting new industry partners for co-development
- None.
CDX Development Update
LONDON, UNITED KINGDOM / ACCESSWIRE / September 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)("Hemogenyx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, is pleased to announce that it has developed a new and improved version of its bi-specific antibody ("CDX") for the treatment of relapsed/refractory acute myeloid leukaemia ("AML"), a subset of acute lymphoblastic leukaemia ("ALL"), and potentially for conditioning in bone marrow transplantations.
The Company's scientists utilised Lonza's bYlok bispecific pairing technology to develop a new and improved version of CDX, which has demonstrated significantly enhanced efficacy in in vitro testing. Additional in vivo studies are currently underway.
Dr. Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals, commented:
"The development of an improved version of our CDX bi-specific antibody holds significant promise for enhancing treatment outcomes for patients battling often incurable blood cancers. This advancement could accelerate the progress of this product candidate and allow us to resume its development toward the clinic. It may also attract new industry partners interested in fast-tracking the co-development of CDX."
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
About AML
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than
About ALL
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that primarily affects children, although it can also occur in adults. Unlike Acute Myeloid Leukemia (AML), ALL is characterized by the rapid proliferation of immature lymphocytes, a type of white blood cell. ALL is the most common childhood cancer, representing approximately
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
What is the latest development in Hemogenyx Pharmaceuticals' CDX antibody?
What conditions could Hemogenyx Pharmaceuticals' improved CDX antibody potentially treat?
What is the current status of Hemogenyx Pharmaceuticals' CDX antibody development?
How might the improved CDX antibody impact Hemogenyx Pharmaceuticals' business prospects?
